Patents by Inventor Shanchun Zhang

Shanchun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11491232
    Abstract: The present disclosure relates to the field of pharmaceutical chemistry, and particularly to a compound represented by Formula (I), a preparation method and medical use thereof. In the compound represented by Formula (I), a lactulosyl group is connected to a heteroatom of genin (G) via a glycosidic bond, wherein the genin (G) is a group formed by removing one hydrogen atom from a heteroatom of an active pharmaceutical molecule, and “” indicates that the lactulosyl group is connected to the heteroatom of the genin (G) via an ?-glycosidic bond or a ?-glycosidic bond. Pharmacokinetic experiments prove that the lactuloside compound according to the present disclosure can pass through the gastrointestinal tract of a mammal without being absorbed significantly by the gastrointestinal tract and hydrolyzed significantly by endogenous enzymes of a mammal host. Therefore, the lactuloside compound can arrive at the colon site of the mammal, and release an active drug in the colon under the action of colon flora.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 8, 2022
    Assignee: Fruithy Holdings Limited
    Inventors: Shanchun Zhang, Jiashi Peng, Bin Yang, Yihua Wang, Min Xu, Xiao Wang, Kaisheng Cheng
  • Patent number: 11084790
    Abstract: The present invention provides a complex of formula (I) or a solvate thereof (wherein n is 1 to 4), a pharmaceutical composition, and use of the pharmaceutical composition in the prevention or treatment of surgical pain, intraoperative pain and postsurgical pain. The technical solution according to the present invention provides a medicament which can be produced by a simple production process and can stably release a local anesthetic in body for a long period. The medicament can be released for at least three days or more, which can prolong the analgesic effect on the postsurgical pain, can be used conveniently by the physician and the patient, and has a good treatment compliance.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 10, 2021
    Assignee: Fruithy Holdings Limited
    Inventors: Shanchun Zhang, Yihua Wang, Jiashi Peng, Kaisheng Cheng, Xiao Wang, Shu Gao, Hongzhang Sun, Xiaorong Lu
  • Publication number: 20210087144
    Abstract: The present invention provides a complex of formula (I) or a solvate thereof (wherein n is 1 to 4), a pharmaceutical composition, and use of the pharmaceutical composition in the prevention or treatment of surgical pain, intraoperative pain and postsurgical pain. The technical solution according to the present invention provides a medicament which can be produced by a simple production process and can stably release a local anesthetic in body for a long period. The medicament can be released for at least three days or more, which can prolong the analgesic effect on the postsurgical pain, can be used conveniently by the physician and the patient, and has a good treatment compliance.
    Type: Application
    Filed: March 26, 2018
    Publication date: March 25, 2021
    Inventors: Shanchun Zhang, Yihua Wang, Jiashi Peng, Kaisheng Cheng, Xiao Wang, Shu Gao, Hongzhang Sun, Xiaorong Lu
  • Patent number: 10568892
    Abstract: The present invention relates to the field of natural medicine and pharmaceutical chemistry, and in particular relates to a cycloartane tetracyclic triterpenoid compound (I), a preparation method thereof and the medical use thereof. The pharmacodynamic tests demonstrate that the compound of the present invention has a pharmacodynamic activity on heart and cerebral vessels and can be used to prevent or treat cardiovascular and/or cerebrovascular diseases such as arrhythmia, myocardial infarction, and coronary heart disease or the like.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: February 25, 2020
    Assignees: Hefei Cosource Pharmaceuticals Inc., Hefei Blooming Drug Safety Evaluation Co., Ltd.
    Inventors: Shanchun Zhang, Shu Gao, Xiaorong Lu, Hongzhang Sun, Yijun Bao, Bin Yang, Jiashi Peng
  • Publication number: 20200009258
    Abstract: The present disclosure relates to the field of pharmaceutical chemistry, and particularly to a compound represented by Formula (I), a preparation method and medical use thereof. In the compound represented by Formula (I), a lactulosyl group is connected to a heteroatom of genin (G) via a glycosidic bond, wherein the genin (G) is a group formed by removing one hydrogen atom from a heteroatom of an active pharmaceutical molecule, and “” indicates that the lactulosyl group is connected to the heteroatom of the genin (G) via an ?-glycosidic bond or a ?-glycosidic bond. Pharmacokinetic experiments prove that the lactuloside compound according to the present disclosure can pass through the gastrointestinal tract of a mammal without being absorbed significantly by the gastrointestinal tract and hydrolyzed significantly by endogenous enzymes of a mammal host. Therefore, the lactuloside compound can arrive at the colon site of the mammal, and release an active drug in the colon under the action of colon flora.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 9, 2020
    Inventors: Shanchun Zhang, Jiashi Peng, Bin Yang, Yihua Wang, Min Xu, Xiao Wang, Kaisheng Cheng
  • Publication number: 20190240238
    Abstract: The present invention relates to the field of natural medicine and pharmaceutical chemistry, and in particular relates to a cycloartane tetracyclic triterpenoid compound (I), a preparation method thereof and the medical use thereof. The pharmacodynamic tests demonstrate that the compound of the present invention has a pharmacodynamic activity on heart and cerebral vessels and can be used to prevent or treat cardiovascular and/or cerebrovascular diseases such as arrhythmia, myocardial infarction, and coronary heart disease or the like.
    Type: Application
    Filed: February 3, 2017
    Publication date: August 8, 2019
    Inventors: Shanchun Zhang, Shu Gao, Xiaorong Lu, Hongzhang Sun, Yijun Bao, Bin Yang, Jiashi Peng
  • Publication number: 20070134709
    Abstract: This invention features our discovery on usages of Methylenetetrahydrofolate Reductase (MTHFR) gene polymorphisms in predicting homocysteine (Hcy) level and/or incidence and prognosis of diseases associated with increased Hcy level in a subject, as well as predicting treatment effects of medicines in the category of Angiotension Converting Enzyme Inhibihor (ACEI) with and without combination with B Vitamins. This invention also features our discovery on laboratory and analytical methods that are essential to the above described usages of MTHFR gene polymorphisms. In addition, this invention features a kit that has translated the above discoveries into a practical and reliable tool that can be applied to accomplish the above described usages of MTHFR gene polymorphisms. This invention represents an important step in realizing personalized medicine, with the goal to tailor diagnosis, prevention and treatment strategy to meet individual needs.
    Type: Application
    Filed: December 13, 2006
    Publication date: June 14, 2007
    Inventors: Xiping Xu, Zhian Fang, Shanqun Jiang, Binyan Wang, Jianhua Yang, Shanchun Zhang, Guangyun Mao, Houxun Xing, Ping Liu, Yan Wang, Tonghua Zang, Mengde Wang, Yu Wang, Chengxiang Dai, Kerong Zhang